Lilly (LLY.US) partners with AdvanCell to advance cancer alpha therapy and improve patient outcomes.

US pharmaceutical giant Eli Lilly and Company (LLY.US) recently announced a collaboration with Australian biotechnology company AdvanCell to co-develop Alpha Therapies for cancer treatment.

AdvanCell is a biotechnology company focused on radiotherapy, with its core technology being the Alpha Isotope Generator, which addresses the biggest challenge in targeted alpha therapy: a stable and scalable isotope supply. This breakthrough technology has the potential to provide cancer patients with more reliable treatment options.

Under the agreement, AdvanCell will provide its Pb-212 (lead-212) production technology and radioactive nucleus development infrastructure, combined with Eli Lilly's pipeline of in-development drugs, to advance a series of targeted alpha therapies. Pb-212 is a radioactive isotope that can be used for precision targeting of cancer cells, reducing damage to healthy tissue, improving efficacy while reducing side effects.

AdvanCell's most advanced candidate drug, ADVC001, is currently in Phase I/II clinical trials, primarily for the treatment of prostate cancer. This collaboration is expected to accelerate the development of the therapy, bringing new treatment hope for cancer patients.